

Organization	Treatment	Clinical Trials	COVID-19 Partnerships	Comment
<a href="https://www.modernatx.com/">Moderna https://www.modernatx.com/</a>	mRNA-1273	Phase I	NIH/NIAID	Kaiser Permanente Washington Health Institute key site
<a href="http://www.cansinotech.com/">CanSino Biologics http://www.cansinotech.com/</a>	Ad5-nCoV	Phase I		Tongi Hospital key site
<a href="http://www.migal.org.il/">MIGAL—Galilee Research Inst. http://www.migal.org.il/</a>	Vaccine from IBV	Preparing for Human Testing	Israeli government	Out of Israeli research & development institute
<a href="https://www.inovio.com/">INOVIO Pharma https://www.inovio.com/</a>	INO-4800	Preclinical	Advaccine Biotechnology (China—manufacturer)	Expects to move to clinical trials in April
<a href="https://www.curevac.com/">CureVac https://www.curevac.com/</a>	mRNA-based target	Preclinical	Working with CEPI	White House tried to buy for exclusive deal
<a href="https://biontech.de/">BioNTech https://biontech.de/</a>	BNT162 (mRNA-based)	Preclinical	Pfizer	Inks partnership with Pfizer
<a href="https://www.gilead.com/">Gilead https://www.gilead.com/</a>	Remdesivir	Multiple trials	Working with several health systems & hospitals	Ebola drug Remdesivir in multiple Phase 3 clinical trials; Wuhan Virology Inst. Sought to patent the therapy
<a href="https://arcturusrx.com/">Arcturus Therapeutics https://arcturusrx.com/</a>	RNA-based	Preclinical		Planning trial ASAP
<a href="https://www.regeneron.com/">Regeneron https://www.regeneron.com/</a>	Targets based on VelocImmune Platform	Discovery	Also working with Sanofi	Human antibodies based on VelocImmune mice—trials by June
<a href="https://www.lilly.com/">Eli Lilly https://www.lilly.com/</a>	Partnering with Canadian firm	Identifying antibodies	AbCellera (Canada)	Plan to have targets in clinical trials within 4 months
<a href="https://www.gsk.com/">GSK https://www.gsk.com/</a>	Licensed proprietary adjuvants to China Licensed IP to Australia	Preclinical	Clover Biopharmaceuticals (China) University of Queensland (Australia)	Not declaring when it can advance any targets to human trials
<a href="https://www.janssen.com/">J&amp;J https://www.janssen.com/</a>	Early stages working with U.S. BARDA	Discovery	U.S. BARDA	Human trials could begin by Nov 2020
<a href="https://www.pfizer.com/">Pfizer https://www.pfizer.com/</a>	Partner approach Internal discovery plus 5-point plan	Preparing	BioNTech (Germany)	Have announced 5-point plan
<a href="https://www.sanofi.com/">Sanofi https://www.sanofi.com/</a>	Internal discovery	Discovery	U.S. BARDA Regeneron (Kevzara)	6 months out before trial
<a href="https://www.takeda.com/en-us/">Takeda https://www.takeda.com/en-us/</a>	Blood/Plasma-based	Discovery		At least 18 months away from treatment
<a href="https://www.vir.bio/">Vir Biotechnology https://www.vir.bio/</a>	SARs survivors isolated antibodies	Discover	WuXi (CRO in China) Alnylam on RNA signaling	Early stages still—no dates or timelines